Literature DB >> 22991965

Ordering of the N-terminus of human MDM2 by small molecule inhibitors.

Klaus Michelsen1, John B Jordan, Jeffrey Lewis, Alexander M Long, Evelyn Yang, Yosup Rew, Jing Zhou, Peter Yakowec, Paul D Schnier, Xin Huang, Leszek Poppe.   

Abstract

Restoration of p53 function through the disruption of the MDM2-p53 protein complex is a promising strategy for the treatment of various types of cancer. Here, we present kinetic, thermodynamic, and structural rationale for the remarkable potency of a new class of MDM2 inhibitors, the piperidinones. While these compounds bind to the same site as previously reported for small molecule inhibitors, such as the Nutlins, data presented here demonstrate that the piperidinones also engage the N-terminal region (residues 10-16) of human MDM2, in particular, Val14 and Thr16. This portion of MDM2 is unstructured in both the apo form of the protein and in MDM2 complexes with p53 or Nutlin, but adopts a novel β-strand structure when complexed with the piperidinones. The ordering of the N-terminus upon binding of the piperidinones extends the current model of MDM2-p53 interaction and provides a new route to rational design of superior inhibitors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22991965     DOI: 10.1021/ja305839b

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  24 in total

1.  Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.

Authors:  Constantinos G Neochoritis; Jack Atmaj; Aleksandra Twarda-Clapa; Ewa Surmiak; Lukasz Skalniak; Lisa-Maria Köhler; Damian Muszak; Katarzyna Kurpiewska; Justyna Kalinowska-Tłuścik; Barbara Beck; Tad A Holak; Alexander Dömling
Journal:  Eur J Med Chem       Date:  2019-08-06       Impact factor: 6.514

Review 2.  Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Authors:  Vladimir N Uversky; Vrushank Davé; Lilia M Iakoucheva; Prerna Malaney; Steven J Metallo; Ravi Ramesh Pathak; Andreas C Joerger
Journal:  Chem Rev       Date:  2014-05-15       Impact factor: 60.622

Review 3.  Pharmacological activation of wild-type p53 in the therapy of leukemia.

Authors:  Kensuke Kojima; Jo Ishizawa; Michael Andreeff
Journal:  Exp Hematol       Date:  2016-06-18       Impact factor: 3.084

4.  The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins.

Authors:  Dima Kozakov; Laurie E Grove; David R Hall; Tanggis Bohnuud; Scott E Mottarella; Lingqi Luo; Bing Xia; Dmitri Beglov; Sandor Vajda
Journal:  Nat Protoc       Date:  2015-04-09       Impact factor: 13.491

5.  Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.

Authors:  Maxim Gureev; Daria Novikova; Tatyana Grigoreva; Svetlana Vorona; Alexander Garabadzhiu; Vyacheslav Tribulovich
Journal:  J Comput Aided Mol Des       Date:  2019-11-28       Impact factor: 3.686

6.  Surface plasmon resonance and cytotoxicity assays of drug efficacies predicted computationally to inhibit p53/MDM2 interaction.

Authors:  Xiaoying Wang; Patrycja Magdziarz; Ernest Enriquez; Wang Zhao; Chris Quan; Narek Darabedian; Jamil Momand; Feimeng Zhou
Journal:  Anal Biochem       Date:  2019-02-02       Impact factor: 3.365

Review 7.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

8.  Monitoring Ligand-Induced Protein Ordering in Drug Discovery.

Authors:  Christy R Grace; David Ban; Jaeki Min; Anand Mayasundari; Lie Min; Kristin E Finch; Lyra Griffiths; Nagakumar Bharatham; Donald Bashford; R Kiplin Guy; Michael A Dyer; Richard W Kriwacki
Journal:  J Mol Biol       Date:  2016-01-23       Impact factor: 5.469

Review 9.  How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.

Authors:  Natalia Estrada-Ortiz; Constantinos G Neochoritis; Alexander Dömling
Journal:  ChemMedChem       Date:  2015-12-16       Impact factor: 3.466

Review 10.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.

Authors:  Yujun Zhao; Angelo Aguilar; Denzil Bernard; Shaomeng Wang
Journal:  J Med Chem       Date:  2014-11-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.